What did @maduheiden actually say?
Honestly, not much. The transcript gives us a single closing line: "I hope you enjoyed this video, see you in the next video!" That's it. The substance of the video lives entirely in the visual before/after comparison and the caption referencing "a diferença" (the difference) about her father, paired with hashtags for Ozempic and Saxenda.
So what we're fact-checking here is the implied claim: that one or both of these GLP-1 medications produced a visible, dramatic physical transformation. The video doesn't explain mechanism, dosing, timeline, or which drug was used. It just shows a result and lets viewers draw their own conclusions.
Does the science back up dramatic GLP-1 results?
Yes, with significant caveats. The clinical evidence for GLP-1 receptor agonists on weight loss is real and reasonably strong, but the two drugs shown in the hashtags are not equivalent, and that distinction matters a lot.
Semaglutide (Ozempic/Wegovy) has the more robust dataset. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants lost an average of 14.9% of body weight over 68 weeks on 2.4mg weekly semaglutide. That's meaningful. Liraglutide (Saxenda), by comparison, produced around 5-7% weight loss in comparable trials (Pi-Sunyer et al., 2015, NEJM). Both drugs suppress appetite through GLP-1 receptor agonism, but semaglutide binds the receptor longer and appears to have stronger central appetite suppression. A before/after video doesn't tell you which drug did the work, over what period, or what else changed.
What did they get wrong, or right?
The video gets the general premise right: these medications can produce visible physical changes in some people. The evidence supports that. But the bundling of Ozempic and Saxenda under a single transformation story is misleading by omission.
- Ozempic is approved for type 2 diabetes in most countries. Wegovy is the weight-loss-approved semaglutide formulation. Using "Ozempic" as shorthand for weight loss treatment, as most social media does, papers over a real regulatory and dosing distinction.
- Saxenda (liraglutide 3mg) and Ozempic (semaglutide 0.5-1mg) are different molecules with different efficacy profiles. Presenting them interchangeably under one transformation implies equivalency that the clinical data doesn't support.
- Before/after content systematically excludes the people who discontinued due to side effects, saw no response, or regained weight after stopping. The STEP 1 trial's follow-up (Wilding et al., 2022, Diabetes Care) showed most participants regained two-thirds of lost weight within a year of stopping semaglutide. That part never makes it into the caption.
What should you actually know?
GLP-1 medications are legitimate tools with real clinical evidence behind them. But viral transformation content strips away everything that makes that evidence meaningful: the trial design, the dropout rates, the side effect profiles, and the question of what happens when you stop.
Nausea, vomiting, and gastrointestinal side effects affect a substantial portion of users. The SCALE Obesity trial for liraglutide (Davies et al., 2015, The Lancet) reported that roughly 40% of participants experienced nausea. For semaglutide, the STEP program reported similar GI rates, with some participants discontinuing treatment.
If you're considering either medication, the conversation belongs with a prescribing clinician who can review your metabolic panel, cardiovascular history, and whether a GLP-1 is actually the right fit for you specifically. A 15-second before/after is not a treatment plan.
The bottom line on before/after GLP-1 content
This video is not dangerous on its own. It doesn't make specific clinical claims. But it contributes to a broader pattern where dramatic results get amplified and the full picture, including regain, side effects, and drug differences, disappears. Viewers seeing this content deserve more context than a hashtag provides.